EE200100314A - Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine - Google Patents

Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine

Info

Publication number
EE200100314A
EE200100314A EEP200100314A EEP200100314A EE200100314A EE 200100314 A EE200100314 A EE 200100314A EE P200100314 A EEP200100314 A EE P200100314A EE P200100314 A EEP200100314 A EE P200100314A EE 200100314 A EE200100314 A EE 200100314A
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
making
pharmaceutical
composition
Prior art date
Application number
EEP200100314A
Other languages
English (en)
Estonian (et)
Inventor
S. Kohn Rachel
J. Hanley Stephen
J. Comiskey Stephen
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of EE200100314A publication Critical patent/EE200100314A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
EEP200100314A 1998-12-16 1999-11-22 Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine EE200100314A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Publications (1)

Publication Number Publication Date
EE200100314A true EE200100314A (et) 2002-08-15

Family

ID=22793267

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100314A EE200100314A (et) 1998-12-16 1999-11-22 Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine

Country Status (35)

Country Link
EP (1) EP1140026B1 (sr)
JP (1) JP4759141B2 (sr)
KR (1) KR100707710B1 (sr)
CN (1) CN1195497C (sr)
AP (1) AP1769A (sr)
AR (1) AR021652A1 (sr)
AT (1) ATE303795T1 (sr)
AU (1) AU770673B2 (sr)
BG (1) BG65500B1 (sr)
BR (1) BR9916276A (sr)
CA (1) CA2355077C (sr)
CR (1) CR6424A (sr)
CZ (1) CZ301947B6 (sr)
DE (1) DE69927177T2 (sr)
DK (1) DK1140026T3 (sr)
EA (1) EA004502B1 (sr)
EE (1) EE200100314A (sr)
ES (1) ES2245128T3 (sr)
HK (1) HK1041645B (sr)
HR (1) HRP20010446A2 (sr)
HU (1) HU226586B1 (sr)
ID (1) ID28909A (sr)
IL (2) IL143761A0 (sr)
ME (2) MEP19408A (sr)
NO (1) NO20012981L (sr)
NZ (1) NZ511962A (sr)
OA (1) OA11728A (sr)
PL (1) PL196822B1 (sr)
RS (1) RS50123B (sr)
SK (1) SK285812B6 (sr)
TR (1) TR200101759T2 (sr)
TW (1) TWI221418B (sr)
UA (1) UA73101C2 (sr)
WO (1) WO2000035423A1 (sr)
ZA (1) ZA200104899B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
US8501056B2 (en) * 2001-05-23 2013-08-06 Hexal Ag Homogenized product for implants and microparticles
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
EP4084607A4 (en) * 2019-12-31 2023-06-21 Wanka Tanka Ltd. EXTENDED RELEASE PLASTIC FORMULATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (sr) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
CR6424A (es) 2004-02-26
WO2000035423A9 (en) 2002-08-22
ME00066B (me) 2010-06-10
TR200101759T2 (tr) 2001-12-21
SK8282001A3 (en) 2001-11-06
DK1140026T3 (da) 2006-01-02
EA200100551A1 (ru) 2001-10-22
HUP0105048A3 (en) 2002-09-30
SK285812B6 (sk) 2007-08-02
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
AP2001002198A0 (en) 2001-09-30
RS50123B (sr) 2009-03-25
KR20010082359A (ko) 2001-08-29
ATE303795T1 (de) 2005-09-15
CA2355077A1 (en) 2000-06-22
CZ301947B6 (cs) 2010-08-11
AU1742500A (en) 2000-07-03
AR021652A1 (es) 2002-07-31
NZ511962A (en) 2003-06-30
ES2245128T3 (es) 2005-12-16
CN1330536A (zh) 2002-01-09
BR9916276A (pt) 2001-09-04
HU226586B1 (en) 2009-04-28
IL143761A (en) 2006-08-01
AP1769A (en) 2007-08-22
TWI221418B (en) 2004-10-01
BG105591A (en) 2002-01-31
JP4759141B2 (ja) 2011-08-31
KR100707710B1 (ko) 2007-04-18
EA004502B1 (ru) 2004-04-29
DE69927177D1 (de) 2005-10-13
HK1041645A1 (en) 2002-07-19
OA11728A (en) 2005-02-01
PL196822B1 (pl) 2008-02-29
JP2002532408A (ja) 2002-10-02
EP1140026B1 (en) 2005-09-07
YU41401A (sh) 2003-12-31
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
NO20012981D0 (no) 2001-06-15
MEP19408A (en) 2010-06-10
DE69927177T2 (de) 2006-06-08
IL143761A0 (en) 2002-04-21
HK1041645B (zh) 2005-07-29
CA2355077C (en) 2009-05-26
UA73101C2 (en) 2005-06-15
HRP20010446A2 (en) 2002-06-30
ZA200104899B (en) 2002-09-16
BG65500B1 (bg) 2008-10-31
AU770673B2 (en) 2004-02-26
CZ20012157A3 (cs) 2001-09-12
NO20012981L (no) 2001-07-27
PL348233A1 (en) 2002-05-20
EP1140026A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
EE03676B1 (et) Mullpakend, selle valmistamise meetod ja mullpakendi kasutamine
EE05021B1 (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE04926B1 (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE200000232A (et) Farmatseutiline kompositsioon ja selle kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE04904B1 (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
FI965039A7 (fi) Uusia trombiini-inhibiittoreita, niiden valmistus ja käyttö
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE200000621A (et) Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
FI981506A0 (fi) Elastomeerikompositio ja sen valmistusmenetelmä
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
FI972264L (fi) Betaiinituote, menetelmä sen valmistamiseksi, ja sen käyttö
EE04346B1 (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04087B1 (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE03387B1 (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
EE200100210A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
GB1A Change in the ownership or in the address of the owner